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The Spike (S) protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) plays
important roles in viral pathogenesis and potentially in the development of an effective vaccine against this
virulent infectious disease. In this study, the codon-optimized S gene of SARS-CoV was synthesized to construct
DNA vaccine plasmids expressing either the full-length or segments of the S protein. High titer S-specific
immunoglobulin G antibody responses were elicited in rabbits immunized with DNA against various segments
of the S protein. Two neutralizing domains were identified on the S protein, one at the N terminus (Ser12-
Thr535) and the other near the C terminus (Arg797-Ile1192).
Severe acute respiratory syndrome (SARS) is a virulent
emerging infectious disease and its etiological agent is a new
human coronavirus (CoV), known as SARS-CoV (8, 13, 14,
16). Developing an effective vaccine is the most cost-effective
approach to achieve protection in a large susceptible popula-
tion (17). The spike (S) protein of SARS-CoV is a candidate
antigen for vaccine development (25). It is a large type-I trans-
membrane glycoprotein containing 23 potential N glycosyla-
tion sites (Fig. 1A) (7, 26) and is responsible for receptor
binding and membrane fusion during virus entry (4, 10, 11, 21,
28). The angiotensin-converting enzyme 2 (ACE2) receptor
was identified as a receptor for SARS-CoV (10), and a small
193-amino-acid fragment of the S protein (Asn318-Val510)
was shown to bind efficiently to ACE2 (24). By using Spike
monoclonal antibody (MAb) 80R, isolated from human anti-
body libraries, a neutralizing region was mapped to Thr261-
Lys672 (19). Additional MAbs, generated by Escherichia coli
over-expressed S fragments, mapped neutralizing epitope to
Scr607-Asn627 (28). A different neutralizing epitope Leu803-
Ala828 was identified with a peptide which had strong binding
to convalescent sera from SARS patients (27). Therefore, it is
important to reconcile such differences by using sequential S
segments expressed by mammalian systems to map the neu-
tralizing domains on S protein.
In this study, DNA immunization was used as an effective
approach to dissect the S neutralizing domains. The codon-
optimized S gene derived from the published sequences (13,
16) was chemically synthesized (Geneart, Regensburg, Ger-
many). DNA vaccine plasmids were subsequently constructed
to express the full-length and different segments of the S pro-
teins (Fig. 1A). There has been no direct experimental evi-
dence to date suggesting that SARS-CoV S protein is cleaved
into S1 and S2 subunits. The designation of S1 (Ser12-Ser798)
and S2 (Arg797-Thr1255) was based on the alignment of the
SARS-CoV S protein sequence with those of other coronavi-
ruses with known cleavage between their S1 and S2 domains
(1, 3, 5, 7, 9, 13, 16). Molecular modeling has proposed a hypo-
thetic division of these two subunits between Leu681-Asp727
(Fig. 1A) (18). S1 was further divided into S1.1 (Ser12-Thr535)
and S1.2 (Gly534-Ser798). S2 contains the most conserved re-
gions, such as the heptad repeat (4, 11, 21, 28), transmembrane
(TM), and cytoplasmic tail. The DNA plasmid with a deletion
of TM, S2.dTM, was also constructed to study the roles of TM
in the S posttranslational processing. The S natural leader was
replaced by the human tissue plasminogen activator (tPA)
leader, which was highly effective in expressing secreted pro-
teins in mammalian cells (2, 15, 22).
All of the codon-optimized S DNA vaccines were highly im-
munogenic in inducing anti-S immunoglobulin G (IgG) in im-
munized New Zealand White rabbits (Fig. 1B and C). It recog-
nized both glycosylated and deglycosylated forms of S proteins,
either transiently expressed from the 293T cells or associated
with SARS-CoV-infected VeroE6 cells (Fig. 1B). Deglycosy-
lation was achieved by using PNGaseF (12, 20). The molecular
weight shifts after deglycosylation for every S segment in the
analysis (Fig. 1B) supported the notion that the SARS-CoV S
protein was glycosylated throughout its entire length (7, 26).
DNA vaccines expressing the full-length S and the N-termi-
nal S1.1 segment elicited high titers, while the S1.2 construct
elicited the lowest titer antibodies in recognizing the full-length
S antigen (Fig. 1C, left). However, the anti-S1.2 titer became high-
er when the autologous S1.2 antigen was used as the enzyme-
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linked immunosorbent assay (ELISA) coating antigen (Fig.
1C, right). This indicates that the S1.2 antigen itself was im-
munogenic but might have poor surface accessibility in the full-
length S protein. In addition, the anti-S sera induced by the full-
length S protein were less effective in recognizing the S1.2 antigen
than that of anti-S1.2 sera (Fig. 1C, right), implying that a large
portion of the anti-S IgG targeted non-S1.2 regions.
The specificity of sera induced by segments of the S protein
was further confirmed by Western blot analysis using recom-
binant S proteins from 293T cells. Rabbit anti-S sera recog-
nized the autologous full-length S protein and each of the S
segments (Fig. 2A). The anti-S1.1 sera recognized the autolo-
gous S1.1 antigen as well as the full-length S antigen and the S1
antigen, which contained the S1.1, but did not recognize the
FIG. 1. (A) Designs of SARS-CoV S DNA vaccines. Schematic representation of the entire S protein is shown at the top, including its natural
leader and a TM close to the C-terminal tail. Hypothesized N glycosylation sites are marked by asterisks, and the ACE2 receptor (R) binding
domain is also noted. DNA vaccines expressing different segments of the S protein are shown in the lower part of the figure, and their amino acid
residue numbers are indicated. The nucleotide boundaries for these constructs are 34 to 3,765 bp for S, 34 to 2,394 bp for S1, 34 to 1,605 bp for
S1.1, 1,599 to 2,394 bp for S1.2, 2,389 to 3,768 bp for S2, and 2,389 to 3,576 bp for S2.dTM. The tPA leader sequence has replaced the S natural
leader in these constructs, and the variant S2.dTM construct has a C-terminal truncation including the TM domain. These codon-optimized S gene
segments were individually subcloned into the DNA vaccine vector pSW3891 (22). (B) Western blot with either viron (Urbani strain)-associated S protein
(SARS-CoV) or various S segments (S, S1, S1.1, and S2) expressed from transiently transfected 293T cells. Uninfected VeroE6 cells were used as negative
controls. Samples were either treated () with the PNGaseF or not treated (), as labeled. Rabbit serum immunized with the full-length S DNA vaccine
was used to detect the SARS-CoV proteins. (C) Titers of rabbit anti-S IgG responses after four DNA immunizations as measured by ELISA. Rabbits
were immunized with a Helios gene gun (Bio-Rad) on the shaved abdominal skin as previously reported (23). Plasmid DNA (36 g) was
administrated to individual rabbits for each of the immunizations at weeks 0, 2, 4, and 8. Serum samples tested were taken at week 10. Two different
S protein antigens, S (left panel) and S1.2 (right panel), expressed from the transiently transfected 293T cells were used as the ELISA coating
antigens. Data represent the geometric mean titers of sera from two different rabbits within each group.
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S1.2 or S2 antigen (Fig. 2B). Similarly, the anti-S1.2 serum
recognized the S1.2 and the two larger S antigens (full-length
S and S1), but not the non-overlapping S1.1 or S2 antigen (Fig.
2C). Finally, the anti-S2 serum recognized the S2 antigen and
to a lesser degree the full-length S antigen but not any of the
other unrelated S segments (Fig. 2D). Three bands were ob-
served in S2 samples (Fig. 2A and D), most likely representing
the monomer, trimer, and an even larger oligomer, based on
their apparent molecular weights. The potential of S2 to form
heat-resistant oligomers was confirmed by an additional exper-
iment in which 4M urea was able to resolve the oligomeric
structures (Fig. 2E). The TM region was important for oli-
FIG. 2. Western blot analysis to identify the specificity of anti-S rabbit sera elicited by DNA vaccines expressing different S segments. (A)
Rabbit serum raised by S DNA vaccine; (B) rabbit serum raised by S1.1 DNA vaccine; (C) rabbit serum raised by S1.2 DNA vaccine; (D) rabbit
serum raised by S2 DNA vaccine. Cell lysates from 293T cells transfected with various S-expressing DNA vaccines and the empty vector are labeled
above each Western blot. All samples were run under denatured conditions. (E) Western blot analysis to compare the potential of S2 and S2.dTM
to form oligomers with rabbit serum immunized with the S2-expressing DNA vaccine. The 293T cell lysates transfected with either of the two S2
DNA constructs were heat (95°C) treated for 5 min prior to their loading onto sodium dodecyl sulfate-polyacrylamide gels; 4M urea was added
to half of the samples (lanes labeled ).
FIG. 3. Western blot analysis of SARS-CoV-associated S proteins
by using rabbit sera elicited by DNA vaccines expressing different S seg-
ments (S, S1.1, S1.2, and S2). Cell-associated viral samples were col-
lected 4 days postinfection and 100 ng of protein was loaded into each
lane for sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Lanes: SARS-CoV, VeroE6 lysate infected with SARS-CoV; VeroE6,
uninfected VeroE6 cells. S, expected monomeric S glycoprotein.
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gomer formations because truncation of the TM would leave
the S2.dTM protein in monomer form (Fig. 2E).
All four rabbit sera, raised either by the full-length S or
segments of the S protein, recognized a dominant band with a
size of approximately 175 kDa in SARS-CoV-infected VeroE6
lysates, as expected from a monomeric S protein (Fig. 3). Our
data demonstrated the possible proteocleavage on the S pro-
tein leading to several smaller low-molecular-weight products
(LMPs), which were detected by anti-S, anti-S1.1, and anti-S1.2
sera but not by anti-S2 sera. Meanwhile, two high-molecular-
weight complexes (HMC1 and HMC2) were observed. The
HMC2 band was detected mainly by the anti-S and anti-S2 sera
but was not effectively detected by the anti-S1.1 and anti-S1.2
sera (Fig. 3). These data support the possibility that the SARS-
CoV-associated S was first cleaved to S1 and S2; S1 was further
cleaved to generate the LMPs, and S2 stayed as oligomers,
which might be stabilized through the C-terminal TM domain
similar to that shown in Fig. 2E. The other high-molecular-
weight complex, HMC1, was recognized by the anti-S, anti-
S1.1, and anti-S1.2 sera and to a lesser extent by the anti-S2
sera, suggesting that HMC1 most likely is an oligomer formed
by the full-length S proteins as reported previously (4, 11, 21,
28) and may serve as the proteocleavage precursor for LMPs
and HMC2.
Neutralization of SARS-CoV infection to VeroE6 cells was
further examined by cytopathic effect (CPE) assay. Sample
pictures of uninfected and infected VeroE6 cells are shown in
Fig. 4A, and the neutralizing titers based on the CPE assay are
summarized in Fig. 4B. The S, S1, and S1.1 DNA vaccines
elicited strong neutralizing antibody responses while the S2
vaccine also elicited positive neutralizing antibody responses.
S1.2 did not elicit significant neutralizing activity against SARS-
CoV, even though there were substantial anti-S1.2 IgG binding
antibodies (Fig. 1C, right). Our data suggested that there were at
least two neutralizing domains on SARS-CoV S protein, one at
the N-terminal S1.1 region and the other at the C-terminal S2
segment.
Our finding of two neutralizing domains in S reconciles re-
cently published findings of a neutralizing domain recognized
by MAbs 80R (19) and S26 and S78 (28), all within the N ter-
FIG. 4. CPE assay to examine the neutralizing antibody responses in DNA-immunized rabbit sera. The neutralization assays were performed
with triplicate testing wells in a 96-well flat-bottom plate in the biosafety level 3 laboratory. SARS-CoV (400 50% tissue culture infective doses)
in 50 l/well was incubated with 50 l of serially diluted rabbit sera or tissue culture medium for 1 h. After the incubation, 100 l of VeroE6 cells
(20,000 cells) was added to each well at a multiplicity of infection of 0.02. The assay results were determined by CPE assay on day 4 of infection.
(A) Sample pictures of uninfected (left) and SARS-CoV-infected VeroE6 cells in the presence (right) or absence (middle) of neutralizing rabbit
serum elicited by DNA vaccine expressing full-length S antigen. (B) Anti-S neutralizing antibody titers of rabbit sera elicited by different S DNA
vaccines. The neutralizing antibody titers are presented as the geometric means of two rabbit sera at the highest antibody dilutions that could
completely prevent CPE.
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minus of S, and the identification of another neutralizing de-
terminant (Leu803-Ala828) within S2 (27). The C-terminal
neutralizing domain has also been detected in another coro-
navirus, mouse hepatitis virus (6). It is not unusual to identify
more than one neutralizing domain on a viral surface protein.
Multiple neutralizing epitopes have been identified on the
human immunodeficiency virus type 1 HIV-1 envelop glyco-
protein, both at the N-terminal gp120 (the V3 loop) and the
C-terminal gp41 (the 2F5 epitope) subunits (29). Our data con-
firmed that DNA immunization is effective in inducing high-
level antibody responses against S glycoprotein as reported
previously (25). This study also suggested the possibility that
the SARS-CoV-associated Spike protein might undergo a step-
wise cleavage to generate S1 and S2 proteins and that cleaved
S2 segments would remain as oligomers. Further study is need-
ed to determine if this process will affect the fusion and entry
of SARS-CoV into targeted cells and whether such cleavage is
cell dependent and tissue specific.
This study was supported in part by NIH grants AI 40337 and AI
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University of Massachusetts Medical School supported by NIH grant
5P30DK32520 from the NIDDKD.
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viding the SARS-CoV Urbani strain for this study.
REFERENCES
1. Bosch, B. J., R. van der Zee, C. A. de Haan, and P. J. Rottier. 2003. The
coronavirus spike protein is a class I virus fusion protein: structural and
functional characterization of the fusion core complex. J. Virol. 77:8801–
8811.
2. Chapman, B. S., R. M. Thayer, K. A. Vincent, and N. L. Haigwood. 1991.
Effect of intron A from human cytomegalovirus (Towne) immediate-early
gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19:
3979–3986.
3. Frana, M. F., J. N. Behnke, L. S. Sturman, and K. V. Holmes. 1985. Pro-
teolytic cleavage of the E2 glycoprotein of murine coronavirus: host-depen-
dent differences in proteolytic cleavage and cell fusion. J. Virol. 56:912–920.
4. Ingallinella, P., E. Bianchi, M. Finotto, G. Cantoni, D. M. Eckert, V. M.
Supekar, C. Bruckmann, A. Carfi, and A. Pessi. 2004. Structural character-
ization of the fusion-active complex of severe acute respiratory syndrome
(SARS) coronavirus. Proc. Natl. Acad. Sci. USA 101:8709–8714.
5. Jackwood, M. W., D. A. Hilt, S. A. Callison, C. W. Lee, H. Plaza, and E.
Wade. 2001. Spike glycoprotein cleavage recognition site analysis of infec-
tious bronchitis virus. Avian Dis. 45:366–372.
6. Koo, M., M. Bendahmane, G. A. Lettieri, A. D. Paoletti, T. E. Lane, J. H.
Fitchen, M. J. Buchmeier, and R. N. Beachy. 1999. Protective immunity
against murine hepatitis virus (MHV) induced by intranasal or subcutaneous
administration of hybrids of tobacco mosaic virus that carries an MHV
epitope. Proc. Natl. Acad. Sci. USA 96:7774–7779.
7. Krokhin, O., Y. Li, A. Andonov, H. Feldmann, R. Flick, S. Jones, U. Stroe-
her, N. Bastien, K. V. Dasuri, K. Cheng, J. N. Simonsen, H. Perreault, J.
Wilkins, W. Ens, F. Plummer, and K. G. Standing. 2003. Mass spectrometric
characterization of proteins from the SARS virus: a preliminary report. Mol.
Cell. Proteomics 2:346–356.
8. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery,
S. Tong, C. Urbani, J. A. Comer, W. Lim, P. E. Rollin, S. F. Dowell, A. E.
Ling, C. D. Humphrey, W. J. Shieh, J. Guarner, C. D. Paddock, P. Rota, B.
Fields, J. DeRisi, J. Y. Yang, N. Cox, J. M. Hughes, J. W. LeDuc, W. J.
Bellini, and L. J. Anderson. 2003. A novel coronavirus associated with severe
acute respiratory syndrome. N. Engl. J. Med. 348:1953–1966.
9. Lai, M. M., and K. Holmes. 2001. Coronarviridae: the viruses and their
replication, p. 1163–1185. In D. Knipe, P. Howley, D. Griffin, R. Lamb, M.
Martin, B. Roizman, and S. Straus (ed.), Fields viology, 4 ed, vol. 1. Lippin-
cott Williams & Wilkins, Baltimore, Md.
10. Li, W., M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M.
Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, H. Choe, and
M. Farzan. 2003. Angiotensin-converting enzyme 2 is a functional receptor
for the SARS coronavirus. Nature 426:450–454.
11. Liu, S., G. Xiao, Y. Chen, Y. He, J. Niu, C. R. Escalante, H. Xiong, J. Farmar,
A. K. Debnath, P. Tien, and S. Jiang. 2004. Interaction between heptad
repeat 1 and 2 regions in spike protein of SARS-associated coronavirus:
implications for virus fusogenic mechanism and identification of fusion in-
hibitors. Lancet 363:938–947.
12. Maley, F., R. B. Trimble, A. L. Tarentino, and T. H. Plummer, Jr. 1989.
Characterization of glycoproteins and their associated oligosaccharides
through the use of endoglycosidases. Anal. Biochem. 180:195–204.
13. Marra, M. A., S. J. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S.
Butterfield, J. Khattra, J. K. Asano, S. A. Barber, S. Y. Chan, A. Cloutier,
S. M. Coughlin, D. Freeman, N. Girn, O. L. Griffith, S. R. Leach, M. Mayo,
H. McDonald, S. B. Montgomery, P. K. Pandoh, A. S. Petrescu, A. G.
Robertson, J. E. Schein, A. Siddiqui, D. E. Smailus, J. M. Stott, G. S. Yang,
F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T. F. Booth, D.
Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray,
A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand,
U. Stroher, G. A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R. C.
Brunham, M. Krajden, M. Petric, D. M. Skowronski, C. Upton, and R. L.
Roper. 2003. The genome sequence of the SARS-associated coronavirus.
Science 300:1399–1404.
14. Peiris, J. S., S. T. Lai, L. L. Poon, Y. Guan, L. Y. Yam, W. Lim, J. Nicholls,
W. K. Yee, W. W. Yan, M. T. Cheung, V. C. Cheng, K. H. Chan, D. N. Tsang,
R. W. Yung, T. K. Ng, and K. Y. Yuen. 2003. Coronavirus as a possible cause
of severe acute respiratory syndrome. Lancet 361:1319–1325.
15. Qiu, J. T., B. Liu, C. Tian, G. N. Pavlakis, and X. F. Yu. 2000. Enhancement
of primary and secondary cellular immune responses against human immu-
nodeficiency virus type 1 gag by using DNA expression vectors that target
Gag antigen to the secretory pathway. J. Virol. 74:5997–6005.
16. Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P.
Icenogle, S. Penaranda, B. Bankamp, K. Maher, M. H. Chen, S. Tong, A.
Tamin, L. Lowe, M. Frace, J. L. DeRisi, Q. Chen, D. Wang, D. D. Erdman,
T. C. Peret, C. Burns, T. G. Ksiazek, P. E. Rollin, A. Sanchez, S. Liffick, B.
Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S.
Gunther, A. D. Osterhaus, C. Drosten, M. A. Pallansch, L. J. Anderson, and
W. J. Bellini. 2003. Characterization of a novel coronavirus associated with
severe acute respiratory syndrome. Science 300:1394–1399.
17. Saif, L. J. 1993. Coronavirus immunogens. Vet. Microbiol. 37:285–297.
18. Spiga, O., A. Bernini, A. Ciutti, S. Chiellini, N. Menciassi, F. Finetti, V.
Causarono, F. Anselmi, F. Prischi, and N. Niccolai. 2003. Molecular mod-
elling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Bio-
chem. Biophys. Res. Commun. 310:78–83.
19. Sui, J., W. Li, A. Murakami, A. Tamin, L. J. Matthews, S. K. Wong, M. J.
Moore, A. St. Clair Tallarico, M. Olurinde, H. Choe, L. J. Anderson, W. J.
Bellini, M. Farzan, and W. A. Marasco. 2004. Potent neutralization of severe
acute respiratory syndrome (SARS) coronavirus by a human mAb to S1
protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 24:
2536–2541.
20. Tarentino, A. L., C. M. Gomez, and T. H. Plummer, Jr. 1985. Deglycosyla-
tion of asparagine-linked glycans by peptide:N-glycosidase F. Biochemistry
24:4665–4671.
21. Tripet, B., M. W. Howard, M. Jobling, R. K. Holmes, K. V. Holmes, and R. S.
Hodges. 2004. Structural characterization of the SARS-coronavirus spike S
fusion protein core. J. Biol. Chem. 279:20836–20849.
22. Wang, S., D. Heilman, F. Liu, T. Giehl, S. Joshi, X. Huang, T. H. Chou, J.
Goguen, and S. Lu. 2004. A DNA vaccine producing LcrV antigen in oli-
gomers is effective in protecting mice from lethal mucosal challenge of
plague. Vaccine 22:3348–3357.
23. Wang, S., S. Joshi, and S. Lu. 2004. Delivery of DNA to skin by particle
bombardment. Methods Mol. Biol. 245:185–196.
24. Wong, S. K., W. Li, M. J. Moore, H. Choe, and M. Farzan. 2004. A 193-
amino acid fragment of the SARS coronavirus S protein efficiently binds
angiotensin-converting enzyme 2. J. Biol. Chem. 279:3197–3201.
25. Yang, Z. Y., W. P. Kong, Y. Huang, A. Roberts, B. R. Murphy, K. Subbarao,
and G. J. Nabel. 2004. A DNA vaccine induces SARS coronavirus neutral-
ization and protective immunity in mice. Nature 428:561–564.
26. Ying, W., Y. Hao, Y. Zhang, W. Peng, E. Qin, Y. Cai, K. Wei, J. Wang, G.
Chang, W. Sun, S. Dai, X. Li, Y. Zhu, J. Li, S. Wu, L. Guo, J. Dai, P. Wan,
T. Chen, C. Du, D. Li, J. Wan, X. Kuai, W. Li, R. Shi, H. Wei, C. Cao, M. Yu,
H. Liu, F. Dong, D. Wang, X. Zhang, X. Qian, Q. Zhu, and F. He. 2004.
Proteomic analysis on structural proteins of severe acute respiratory syn-
drome coronavirus. Proteomics 4:492–504.
27. Zhang, H., G. Wang, J. Li, Y. Nie, X. Shi, G. Lian, W. Wang, X. Yin, Y. Zhao,
X. Qu, M. Ding, and H. Deng. 2004. Identification of an antigenic determi-
nant on the S2 domain of the severe acute respiratory syndrome coronavirus
spike glycoprotein capable of inducing neutralizing antibodies. J. Virol. 78:
6938–6945.
28. Zhou, T., H. Wang, D. Luo, T. Rowe, Z. Wang, R. J. Hogan, S. Qiu, R. J.
Bunzel, G. Huang, V. Mishra, T. G. Voss, R. Kimberly, and M. Luo. 2004. An
exposed domain in the severe acute respiratory syndrome coronavirus spike
protein induces neutralizing antibodies. J. Virol. 78:7217–7226.
29. Zolla-Pazner, S. 2004. Identifying epitopes of HIV-1 that induce protective
antibodies. Nat. Rev. Immunol. 4:199–210.
1910 NOTES J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
